Tvardi Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of small molecule therapeutics that selectively target key proteins in the complement pathway. Founded in 2014, the company’s research efforts center on oral inhibitors of complement C2 and C3, with the goal of providing convenient, non-injectable treatment options for patients suffering from life-threatening complement-mediated diseases. Tvardi’s lead asset, TVT-019, is a novel small molecule C2 inhibitor currently advancing through Phase 1 clinical trials for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder characterized by chronic hemolysis and thrombotic risk.
In addition to its PNH program, Tvardi is pursuing broader indications for its oral complement inhibitors, including geographic and age-related macular degeneration, cold agglutinin disease, and autoimmune conditions. The company leverages a proprietary platform that enables rapid screening and optimization of small molecules against complement targets, supported by preclinical collaborations with academic institutions and contract research organizations. Tvardi’s integrated model combines medicinal chemistry, in vitro screening, and in vivo pharmacology to streamline candidate selection and de-risk development milestones.
Headquartered in Vancouver, British Columbia, Tvardi maintains a research presence in Colorado and a corporate office in Boston, Massachusetts, to facilitate regulatory interactions and clinical collaborations within North America and Europe. Under the leadership of Chief Executive Officer Brian M. Griffith and Chief Scientific Officer Dr. Lisa Harvey, the company has built a multidisciplinary team with expertise in immunology, hematology, and ophthalmology. Tvardi continues to expand its pipeline through internal discovery efforts and strategic partnerships aimed at addressing unmet needs in complement-driven diseases worldwide.
AI Generated. May Contain Errors.
